TITLE:
Efficacy of 2LPAPI®, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection
AUTHORS:
Gilles Thomas, Hélène Cluzel, Jacqueline Lafon, Jacques Bruhwyler, Béatrice Lejeune
KEYWORDS:
High-Risk Human Papillomavirus, Micro-Immunotherapy, Genital Infection, Homeopathy, 2LPAPI®
JOURNAL NAME:
Advances in Infectious Diseases,
Vol.6 No.1,
March
18,
2016
ABSTRACT: Human papillomaviruses
(HPVs) are well known for being linked to the development of cervical cancers,
most of them being caused by the high-risk (HR) oncogenic genotypes, mainly 16
and 18. The efficacy of 2LPAPI®(Labo’Life), a micro-immunotherapy
homeopathic drug, has been evaluated in HR-HPV infected women (n = 18), in a
private gynecology practice, by comparing them to an untreated control group (n
= 18). Patients were 20 to 45 years old and had cytology with Atypical Squamous
Cells of Undetermined Significance (ASCUS) or Low grade Superficial Intra
Lesions/ Cervical Intraepithelial Neoplasia Grade I (LSIL/CINI). Patients
freely chose to be treated with the drug or not. Those deciding not to take the
drug remained untreated and were followed as a control group. The drug was
taken at the regimen of one capsule per day during 6 months. HR-HPV and
cytology were evaluated at 6 and 12 months. After 12 months, HR-HPV was cleared
in 78% of the patients taking the drug versus 44% in those not taking it (p =
0.086). In patients over 25 years, HR-HPV clearance in the treated group was
significantly higher (81.3%) than in the control group (20%) (p = 0.004). The difference
in the regression of the lesion grades almost reached statistical significance
(p = 0.053). This follow-up confirms that the micro-immunotherapy drug 2LPAPI® is a safe and effective therapeutic
approach to treat HR-HPV cervical lesions in women over 25 years.